Safety and Efficacy of Subcutaneous Daratumumab in Systemic AL Amyloidosis

References

• Chakraborty R, Lentzsch S. Emerging drugs for the treatment of light chain amyloidosis. Expert Opin Emerg Drugs. 2020;25(3):299–317. doi:10.1080/14728214.2020.1803829
   PubMed Web of Science ®Google Scholar
• Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med. 2003;349(6):583–596. doi:10.1056/NEJMra023144
   PubMed Web of Science ®Google Scholar
• Merlini G. AL amyloidosis: from molecular mechanisms to targeted therapies. Hematology Am Soc Hematol Educ Program. 2017;2017(1):1–12. doi:10.1182/asheducation-2017.1.1
   PubMed Web of Science ®Google Scholar
• Kourelis TV, Dasari S, Theis JD, et al. Clarifying immunoglobulin gene usage in systemic and localized immunoglobulin light-chain amyloidosis by mass spectrometry. Blood. 2017;129(3):299–306. doi:10.1182/blood-2016-10-743997
   PubMed Web of Science ®Google Scholar
• Oliva L, Orfanelli U, Resnati M, et al. The amyloidogenic light chain is a stressor that sensitizes plasma cells to proteasome inhibitor toxicity. Blood. 2017;129(15):2132–2142. doi:10.1182/blood-2016-08-730978
   PubMed Web of Science ®Google Scholar
• Genereux JC, Qu S, Zhou M, et al. Unfolded protein response-induced ER dj3 secretion links ER stress to extracellular proteostasis. EMBO J. 2015;34(1):4–19. doi:10.15252/embj.201488896
   PubMed Web of Science ®Google Scholar
• Kazman P, Absmeier RM, Engelhardt H, et al. Dissection of the amyloid formation pathway in AL amyloidosis. Nat Commun. 2021;12(6516). doi:10.1038/s41467-021-26845-0.
   Google Scholar
• Rawat P, Prabakaran R, Kumar S, et al. Exploring the sequence features determining amyloidosis in human antibody light chains. Sci Rep. 2021;11(13785). doi:10.1038/s41598-021-93019-9.
   Google Scholar
• Palladini G, Lavatelli F, Russo P, et al. Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL. Blood. 2006;107(10):3854–3858. doi:10.1182/blood-2005-11-4385
   PubMed Web of Science ®Google Scholar
• Kyle RA, Larson DR, Kurtin PJ, et al. Incidence of AL Amyloidosis in Olmsted County, Minnesota, 1990 through 2015. Mayo Clin Proc. 2019;94(3):465–471. doi:10.1016/j.mayocp.2018.08.041
   PubMed Web of Science ®Google Scholar
• Ravichandran S, Lachmann HJ, Wechalekar AD. Epidemiologic and survival trends in Amyloidosis, 1987–2019. N Engl J Med. 2020;382(16):1567–1568. doi:10.1056/NEJMc1917321
   PubMed Web of Science ®Google Scholar
• Gertz MA. Immunoglobulin light chain amyloidosis: 2022 update on diagnosis, prognosis, and treatment. Am J Hematol. 2022;97(6):818–829. doi:10.1002/ajh.26569
   PubMed Web of Science ®Google Scholar
• Staron A, Zheng L, Doros G, et al. Marked progress in AL amyloidosis survival: a 40-year longitudinal natural history study. Blood Cancer J. 2021;11(139). doi:10.1038/s41408-021-00529-w.
   PubMedGoogle Scholar
• Gertz MA, Cohen AD, Comenzo RL, et al. Results of the Phase 3 VITAL study of NEOD001 (Birtamimab) plus standard of care in patients with Light Chain (AL) Amyloidosis suggest survival benefit for mayo stage IV patients. Blood. 2019;134(Supplement_1):3166. doi:10.1182/blood-2019-124482
   Google Scholar
• Kumar S, Dispenzieri A, Lacy MQ, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol. 2012;30(9):989–995. doi:10.1200/JCO.2011.38.5724
   PubMed Web of Science ®Google Scholar
• Kyle RA, Gertz MA, Greipp PR, et al. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med. 1997;336(17):1202–1207. doi:10.1056/NEJM199704243361702
   PubMed Web of Science ®Google Scholar
• Sidiqi MH, Aljama MA, Buadi FK, et al. Stem cell transplantation for light chain amyloidosis: decreased early mortality over time. J Clin Oncol. 2018;36(13):1323–1329. doi:10.1200/JCO.2017.76.9554
   PubMed Web of Science ®Google Scholar
• Reece DE, Sanchorawala V, Hegenbart U, et al. Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a Phase 1 dose-escalation study. Blood. 2009;114(8):1489–1497. doi:10.1182/blood-2009-02-203398
   PubMed Web of Science ®Google Scholar
• Manwani R, Cohen O, Sharpley F, et al. A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib. Blood. 2019;134(25):2271–2280. doi:10.1182/blood.2019000834
   PubMed Web of Science ®Google Scholar
• Palladini G, Milani P, Foli A, et al. Presentation and outcome with second-line treatment in AL amyloidosis previously sensitive to nontransplant therapies. Blood. 2018;131(5):525–532. doi:10.1182/blood-2017-04-780544
   PubMed Web of Science ®Google Scholar
• Lokhorst HM, Plesner T, Laubach JP, et al. Targeting CD38 with daratumumab monotherapy in multiple myeloma. N Engl J Med. 2015;373(13):1207–1219. doi:10.1056/NEJMoa1506348
   PubMed Web of Science ®Google Scholar
• Deaglio S, Vaisitti T, Billington R, et al. CD38/CD19: a lipid raft-dependent signaling complex in human B cells. Blood. 2007;109(12):5390–5398. doi:10.1182/blood-2006-12-061812
   PubMed Web of Science ®Google Scholar
• DARZALEX [Package Insert]. Washington D.C: Food and Drug Administration; 2022.
   Google Scholar
• Sanchez L, Wang Y, Siegel DS, et al. Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma. J Hematol Oncol. 2016;9(51). doi:10.1186/s13045-016-0283-0.
   Google Scholar
• Van Wagoner CM, Rivera-Escalera F, Jaimes-Delgadillo NC, et al. Antibody-mediated phagocytosis in cancer immunotherapy. Immunol Rev. 2023;319(1):128–141. doi:10.1111/imr.13265
   PubMed Web of Science ®Google Scholar
• Overdijk MB, Jansen JH, Nederend M, et al. The therapeutic CD38 monoclonal antibody daratumumab induces programmed cell death via Fcgamma receptor-mediated cross-linking. J Immunol. 2016;197(3):807–813. doi:10.4049/jimmunol.1501351
   PubMed Web of Science ®Google Scholar
• Overdijk MB, Verploegen S, Bogels M, et al. Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma. MAbs. 2015;7(2):311–321. doi:10.1080/19420862.2015.1007813
   PubMed Web of Science ®Google Scholar
• Shah UA, Mailankody S. Emerging immunotherapies in multiple myeloma. BMJ. 2020;370(m3176). doi:10.1136/bmj.m3176
   Google Scholar
• de Weers M, Tai Y-T, van der Veer MS, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol. 2011;186(3):1840–1848. doi:10.4049/jimmunol.1003032
   PubMed Web of Science ®Google Scholar
• Prejzner W, Piekos O, Beldzinska K, et al. The role of daratumumab in relapsed/refractory CD38 positive acute leukemias-case report on three cases with a literature review. Front Oncol. 2023;13(1228481). doi:10.3389/fonc.2023.1228481.
   PubMedGoogle Scholar
• Yang EH, Muhsen IN, Samarkandi H, et al. Role of anti-CD38 monoclonal antibodies in the treatment of adult immune hematological diseases. Hematol Oncol Stem Cell Ther. 2023;17(1):4–12. doi:10.56875/2589-0646.1108
   PubMedGoogle Scholar
• Zhao D, Guo Z, Zhao G, et al. A novel daratumumab-based regimen for desensitization in highly HLA-presensitized patients awaiting kidney transplantation. Transpl Int. 2023;36(11771). doi:10.3389/ti.2023.11771.
   PubMedGoogle Scholar
• Nocturne G, Marmontel O, Di Filippo M, et al. Efficacy of daratumumab in refractory primary Sjogren disease. RMD Open. 2023;9(3):e003464. doi:10.1136/rmdopen-2023-003464
   PubMed Web of Science ®Google Scholar
• Al-Samkari H, Neufeld EJ. Novel therapeutics and future directions for refractory immune thrombocytopenia. Br J Haematol. 2023;203(1):65–78. doi:10.1111/bjh.19078
   PubMed Web of Science ®Google Scholar
• DARZALEX FASPRO [Package Insert]. Washington D.C: Food and Drug Administration; 2020.
   Google Scholar
• Medicare Part B ASP Drug Cost. HCPCS J-Code: J9145 (Daratumumab). Center for Medicare and Medicaid Services; 2020.
   Google Scholar
• Gordan LN, Marks SM, Xue M, et al. Daratumumab utilization and cost analysis among patients with multiple myeloma in a US community oncology setting. Future Oncol. 2022;18(3):301–309. doi:10.2217/fon-2021-1072
   PubMed Web of Science ®Google Scholar
• Medicare Part B ASP Drug Cost. HCPCS J-Code: J9070 (Cyclophosphamide). Center for Medicare and Medicaid Services; 2023.
   Google Scholar
• Medicare Part B ASP Drug Cost. HCPCS J-Code: J9041 (Bortezomib). Center for Medicare and Medicaid Services; 2023.
   Google Scholar
• Moreau P, Hulin C, Perrot A, et al. Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial. Lancet Oncol. 2021;22(10):1378–1390. doi:10.1016/S1470-2045(21)00428-9
   PubMed Web of Science ®Google Scholar
• Facon T, Kumar SK, Plesner T, et al. Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(11):1582–1596. doi:10.1016/S1470-2045(21)00466-6
   PubMed Web of Science ®Google Scholar
• Voorhees PM, Kaufman JL, Laubach J, et al. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood. 2020;136(8):936–945. doi:10.1182/blood.2020005288
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Oriol A, Nahi H, et al. Overall survival with daratumumab, lenalidomide, and dexamethasone in previously treated multiple myeloma (POLLUX): a randomized, open-label, Phase III trial. J Clin Oncol. 2023;41(8):1590–1599. doi:10.1200/JCO.22.00940
   PubMed Web of Science ®Google Scholar
• Sonneveld P, Chanan-Khan A, Weisel K, et al. Overall survival with daratumumab, bortezomib, and dexamethasone in previously treated multiple myeloma (CASTOR): a randomized, open-label, Phase III trial. J Clin Oncol. 2023;41(8):1600–1609. doi:10.1200/JCO.21.02734
   PubMed Web of Science ®Google Scholar
• Sher T, Fenton B, Akhtar A, et al. First report of safety and efficacy of daratumumab in 2 cases of advanced immunoglobulin light chain amyloidosis. Blood. 2016;128(15):1987–1989. doi:10.1182/blood-2016-06-722496
   PubMed Web of Science ®Google Scholar
• Kaufman GP, Schrier SL, Lafayette RA, et al. Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis. Blood. 2017;130(7):900–902. doi:10.1182/blood-2017-01-763599
   PubMed Web of Science ®Google Scholar
• Sanchorawala V, Sarosiek S, Schulman A, et al. Safety, tolerability, and response rates of daratumumab in relapsed AL amyloidosis: results of a Phase 2 study. Blood. 2020;135(18):1541–1547. doi:10.1182/blood.2019004436
   PubMed Web of Science ®Google Scholar
• Roussel M, Merlini G, Chevret S, et al. A prospective phase 2 trial of daratumumab in patients with previously treated systemic light-chain amyloidosis. Blood. 2020;135(18):1531–1540. doi:10.1182/blood.2019004369
   PubMed Web of Science ®Google Scholar
• Kaufman GP, Dispenzieri A, Gertz MA, et al. Kinetics of organ response and survival following normalization of the serum free light chain ratio in AL amyloidosis. Am J Hematol. 2015;90(3):181–186. doi:10.1002/ajh.23898
   PubMed Web of Science ®Google Scholar
• Lonial S, Weiss BM, Usmani SZ, et al. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet. 2016;387(10027):1551–1560. doi:10.1016/S0140-6736(15)01120-4
   PubMed Web of Science ®Google Scholar
• Darzalex. Amsterdam. Netherlands: European Medicines Agency; 2023.
   Google Scholar
• Chari A, Rodriguez-Otero P, McCarthy H, et al. Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open-label Phase II study. Br J Haematol. 2021;192(5):869–878. doi:10.1111/bjh.16980
   PubMed Web of Science ®Google Scholar
• Report submitted 6/5/2020 to the Vermont office of the attorney general for introduction of a new prescription drug to market. Vermont: Janssen Biotech, Inc; 2020.
   Google Scholar
• Usmani SZ, Nahi H, Mateos MV, et al. Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma. Blood. 2019;134(8):668–677. doi:10.1182/blood.2019000667
   PubMed Web of Science ®Google Scholar
• Mateos MV, Nahi H, Legiec W, et al. Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial. Lancet Haematol. 2020;7(5):e370–e380. doi:10.1016/S2352-3026(20)30070-3
   PubMed Web of Science ®Google Scholar
• Kastritis E, Palladini G, Minnema MC, et al. Daratumumab-based treatment for immunoglobulin light-chain amyloidosis. N Engl J Med. 2021;385(1):46–58. doi:10.1056/NEJMoa2028631
   PubMed Web of Science ®Google Scholar
• Chakraborty R, Rosenbaum C, Kaur G, et al. First report of outcomes in patients with stage I IIb AL amyloidosis treated with Dara–VCD front-line therapy. Br J Haematol. 2023;201(5):913–916. doi:10.1111/bjh.18733
   PubMed Web of Science ®Google Scholar
• Maura F, Boyle EM, Coffey D, et al. Genomic and immune signatures predict clinical outcome in newly diagnosed multiple myeloma treated with immunotherapy regimens. Nat Cancer. 2023. doi:10.1038/s43018-023-00657-1
   PubMedGoogle Scholar
• Seckinger A, Hillengass J, Emde M, et al. CD38 as immunotherapeutic target in light chain amyloidosis and multiple myeloma-association with molecular entities, risk, survival, and mechanisms of upfront resistance. Front Immunol. 2018;9(1676). doi:10.3389/fimmu.2018.01676.
   PubMedGoogle Scholar
• van de Donk N, Usmani SZ. CD38 antibodies in multiple myeloma: mechanisms of action and modes of resistance. Front Immunol. 2018;9(2134). doi:10.3389/fimmu.2018.02134
   PubMedGoogle Scholar
• De Novellis D, Fontana R, Palmieri S, et al. Safety of subcutaneous daratumumab in anti-CD38 monoclonal antibody-naive patients with plasma cell disorders: a multicenter real-life experience. Target Oncol. 2023;18(6):885–892. doi:10.1007/s11523-023-01001-4
   PubMed Web of Science ®Google Scholar
• Abeykoon JP, Zanwar S, Dispenzieri A, et al. Daratumumab-based therapy in patients with heavily-pretreated AL amyloidosis. Leukemia. 2019;33(2):531–536. doi:10.1038/s41375-018-0262-2
   PubMed Web of Science ®Google Scholar
• Al Saleh AS, Ebraheem MS, Sidiqi MH, et al. Treatment and outcomes of patients with light chain amyloidosis who received a second line of therapy post autologous stem cell transplantation. Blood Cancer J. 2022;12(59). doi:10.1038/s41408-022-00655-z.
   PubMedGoogle Scholar
• Chung A, Kaufman GP, Sidana S, et al. Organ responses with daratumumab therapy in previously treated AL amyloidosis. Blood Adv. 2020;4(3):458–466. doi:10.1182/bloodadvances.2019000776
   PubMed Web of Science ®Google Scholar
• Cohen OC, Brodermann MH, Blakeney IJ, et al. Rapid response to single agent daratumumab is associated with improved progression-free survival in relapsed/refractory AL amyloidosis. Amyloid. 2020;27(3):200–205. doi:10.1080/13506129.2020.1765768
   PubMed Web of Science ®Google Scholar
• Gounot R, Le Bras F, Dupuis J, et al. Daratumumab is safe and induces a rapid hematological response in light-chain amyloidosis with severe cardiac impairment. Leuk Lymphoma. 2021;62(4):979–983. doi:10.1080/10428194.2020.1850717
   PubMed Web of Science ®Google Scholar
• Kastritis E, Rousakis P, Kostopoulos IV, et al. Consolidation with a short course of daratumumab in patients with AL amyloidosis or light chain deposition disease. Amyloid. 2021;28(4):259–266. doi:10.1080/13506129.2021.1971192
   PubMed Web of Science ®Google Scholar
• Kimmich CR, Terzer T, Benner A, et al. Daratumumab for systemic AL amyloidosis: prognostic factors and adverse outcome with nephrotic-range albuminuria. Blood. 2020;135(18):1517–1530. doi:10.1182/blood.2019003633
   PubMed Web of Science ®Google Scholar
• Kimmich CR, Terzer T, Benner A, et al. Daratumumab, lenalidomide, and dexamethasone in systemic light-chain amyloidosis: high efficacy, relevant toxicity and main adverse effect of gain 1q21. Am J Hematol. 2021;96(7):E253–E257. doi:10.1002/ajh.26191
   PubMed Web of Science ®Google Scholar
• Lecumberri R, Krsnik I, Askari E, et al. Treatment with daratumumab in patients with relapsed/refractory AL amyloidosis: a multicentric retrospective study and review of the literature. Amyloid. 2020;27(3):163–167. doi:10.1080/13506129.2020.1730791
   PubMed Web of Science ®Google Scholar
• Milani P, Fazio F, Basset M, et al. High rate of profound clonal and renal responses with daratumumab treatment in heavily pre-treated patients with light chain (AL) amyloidosis and high bone marrow plasma cell infiltrate. Am J Hematol. 2020;95(8):900–905. doi:10.1002/ajh.25828
   PubMed Web of Science ®Google Scholar
• Sammartano V, Antonioli E, Buda G, et al. Daratumumab in AL amyloidosis: a real-life experience of the ”RTM” (Regional Tuscan Myeloma Network). J Pers Med. 2022;12(3):484. doi:10.3390/jpm12030484
   PubMed Web of Science ®Google Scholar
• Shragai T, Gatt M, Lavie N, et al. Daratumumab for relapsed AL amyloidosis-when cumulative real-world data precedes clinical trials: a multisite study and systematic literature review. Eur J Haematol. 2021;106(2):184–195. doi:10.1111/ejh.13535
   PubMed Web of Science ®Google Scholar
• Szalat RE, Gustine J, Sloan JM, et al. Predictive factors of outcomes in patients with AL amyloidosis treated with daratumumab. Am J Hematol. 2022;97(1):79–89. doi:10.1002/ajh.26399
   PubMed Web of Science ®Google Scholar